SerpApi.Org
Samsung Biologics announced Sunday it would pay CHF 1.46 billion ($1.81 billion) in an all-cash tender offer to acquire PolyPeptide Group AG, a Swiss contract drug manufacturer that builds the molecular ingredients at the heart of the GLP-1 obesity and diabetes drugs that tens of millions of patients rely on — meaning Samsung is not just buying a company but a foothold in one of the most constrained supply chains in modern medicine. The deal, confirmed by Bloomberg and CNBC on Monday, is the largest biopharma acquisition in South Korean history.
The offer price of CHF 44.31 per share represents a 40% premium above the last price PolyPeptide traded before acquisition rumors began circulating in April, and a 6.1% premium above last Friday's close. PolyPeptide's board, acting through its independent and non-conflicted members, unanimously recommended shareholders accept. The company's largest shareholder, controlling approximately 55.65% of outstanding shares, has already committed irrevocably to tender — effectively guaranteeing the deal clears the required two-thirds acceptance threshold. PolyPeptide shares rose approximately 5.3% in Monday trading, while Samsung Biologics shares fell 3.4% in Seoul, slightly outperforming a broader KOSPI that dropped 4.1% on the day.
Why Making GLP-1 Drugs Is Harder Than It Looks
Semaglutide — the active ingredient in Ozempic and Wegovy — is a chain of 31 amino acids. Tirzepatide, Eli Lilly's version behind Mounjaro and Zepbound, runs to 39 amino acids. Both sit near the upper limit of what solid-phase peptide synthesis, or SPPS, handles comfortably.
SPPS is the standard industrial method for making drugs like these. The process begins with a first amino acid anchored to a solid resin bead. Subsequent amino acids are then coupled on one at a time, in exact sequence, through a repeating cycle of chemical reactions, washes, and deprotection steps. Building semaglutide or tirzepatide requires 30 to 40 or more of these cycles before the completed chain is cleaved from the resin, purified at scale using industrial high-performance liquid chromatography, and dried by freeze-drying. The fatty-acid modifications that give these drugs their long duration of action must be added afterward in separate chemical steps.
None of this resembles the large-molecule antibody manufacturing that built Samsung Biologics' reputation. Antibody drugs are grown in tanks of mammalian cells — bioreactors using Chinese hamster ovary cell lines, in most cases. Peptide drugs are chemically assembled in specialized reactor vessels handling organic solvents, with different analytical instrumentation, different purification equipment, and entirely different regulatory validation requirements. Samsung's 845,000 liters of global bioreactor capacity — the measure by which it ranks as the world's largest biologics CDMO — is effectively irrelevant to making semaglutide.
What matters is whether a company has Good Manufacturing Practice-certified SPPS suites, and whether those suites have already been inspected and validated by regulators across multiple jurisdictions. Building that infrastructure from scratch typically takes several years of engineering, construction, and regulatory validation. Buying it compresses that timeline to the months it takes to close a deal.
What Samsung Is Actually Buying
PolyPeptide has been making peptide active pharmaceutical ingredients since 1952. That means more than 70 years of accumulated peptide chemistry expertise, and a portfolio that now spans more than 1,000 therapeutic peptides produced to date. Its six GMP-certified manufacturing facilities span Sweden, Belgium, France, the United States, and India.
The Belgium facility is particularly significant. PolyPeptide brought a large-scale SPPS plant online in Braine-l'Alleud in the second half of 2024, with projects underway to double SPPS capacity at its Strasbourg and Malmö sites as well. Those expansion projects were driven by a multi-year commercial GLP-1 agreement requiring substantial capital investment over three years.
The timing of the acquisition announcement alongside PolyPeptide's preliminary first-half 2026 results provides striking context for why Samsung acted now. Revenue in the first six months of 2026 reached EUR 236.6 million — a 41.6% increase over the prior-year period. The EBITDA margin improved to 20.7%. Metabolic therapeutics — the segment that includes GLP-1 drugs — grew to approximately 68% of total revenue in the first half of 2026, compared with 56% a year earlier. Samsung is acquiring a company whose revenue is accelerating sharply at precisely the moment it is most valuable.
How the GLP-1 Supply Crunch Made This Deal Inevitable
The FDA placed semaglutide injections on its official drug shortage list in 2022, reflecting a mismatch between how fast the drugs were being prescribed and how fast pharmaceutical manufacturers could make them. GLP-1 prescriptions grew by roughly 442% between January 2021 and December 2023. The formal shortage was declared resolved on February 21, 2025, but the resolution reflected enormous ongoing investment rather than the return of slack capacity. The supply chain remains structurally tight.
At the core of the bottleneck is what makes SPPS different from other drug manufacturing: it cannot be scaled simply by adding more tanks. New SPPS facilities require specialized construction, customized solvent handling and waste management infrastructure, industrial-scale HPLC purification and lyophilization capacity, and regulatory validation across each production step. Approximately 36% of peptide manufacturers operated at utilization rates above 80% through 2025. The top five peptide CDMO providers collectively controlled approximately 56% of global peptide manufacturing capacity.
That concentration has been intensifying. Bachem, the Swiss market leader in peptide manufacturing, committed CHF 700 million to new facilities between 2023 and 2026. CordenPharma has invested nearly EUR 1 billion in peptide expansion, including a major facility in the Basel region. Lonza has been expanding solid-phase capacity at its US sites. Thermo Fisher has built out peptide API capabilities as well. Samsung's entry via acquisition, rather than greenfield construction, is the fastest possible on-ramp into this competition.
Samsung's Multimodality Pivot Becomes Concrete
Samsung Biologics CEO John Rim signaled the direction at the JPMorgan Healthcare Conference in January 2026, describing the planned Bio Campus III — a 7 trillion Korean won investment program expected to complete by 2034 — as a multimodality site without confirming which drug types would anchor it. This acquisition answers at least part of that question directly: peptide manufacturing, and specifically GLP-1 APIs, will be a pillar of Samsung's next decade.
"This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India," Rim said in a statement.
Samsung Biologics enters the deal from a position of financial strength. The company posted full-year 2025 revenue of KRW 4,557 billion, a 30.3% year-on-year increase supported by full utilization across its biologics plants and the ramp-up of its fifth manufacturing plant. Cumulative contract value has exceeded $21 billion since the company's founding in 2011. The $1.81 billion all-cash offer is significant but manageable at that scale.
The deal also follows Samsung's acquisition of a cGMP manufacturing site in Rockville, Maryland from GSK, announced in December 2025 and completed in March 2026, which gave the company its first US-based manufacturing footprint — a 60,000-liter biologics facility. Absorbing PolyPeptide's European and US peptide plants extends that geographic diversification into a second drug modality simultaneously.
One Market, Fewer Hands: What the Consolidation Wave Means for Patients
The race to control validated GMP-SPPS capacity is narrowing the field of independent peptide manufacturers at exactly the moment more drugs depend on that infrastructure. The global peptide CDMO market is projected to reach $13.4 billion by 2034, growing at a compound annual rate of approximately 10%, with GLP-1 manufacturing accounting for a growing share. More than 33% of recent capacity additions across the industry have been dedicated specifically to metabolic disorder therapeutics.
Consolidation has straightforward near-term benefits: integrated players can direct capital toward expansion faster than smaller independents. But it also concentrates the supply chain around a shrinking number of decision-makers and facilities. If a top-tier CDMO encounters a quality failure, a regulatory hold, or operational disruption, the absence of broadly distributed backup capacity means that disruption propagates directly to patients.
The Samsung-PolyPeptide combination does not by itself resolve the structural capacity gap. PolyPeptide's existing sites operate at their current ceiling, and the capacity expansions underway in Belgium, France, and Sweden will take time to ramp up after the deal closes. What changes immediately is ownership and investment direction — Samsung's financial resources can fund acceleration of those projects in ways that PolyPeptide as an independent listed company could not have sustained as quickly.
Whether this integration produces the next phase of GLP-1 capacity expansion or adds a layer of organizational complexity to facilities that were already performing well will take several years to determine. For patients who depend on these drugs for diabetes management and weight control, the long-term implication is simple: a critical part of their supply chain will increasingly be shaped by decisions made in Songdo, Incheon.
Road to Completion
The formal tender offer prospectus is expected to be published by the end of August 2026, following procedures under Swiss takeover law, including a ten-trading-day cooling-off period. The offer will then remain open for a minimum of twenty trading days on the SIX Swiss Exchange.
Completion is contingent on meeting the 66⅔% acceptance threshold, obtaining regulatory approvals in relevant jurisdictions, and satisfying other customary conditions under Swiss takeover law. With 55.65% already committed, the threshold requires that only approximately 12% of remaining outstanding shares be tendered — a low bar given the unanimous board recommendation and the 40% premium relative to pre-rumor pricing. J.P. Morgan is serving as financial advisor to Samsung Biologics; O'Melveny & Myers LLP and Schellenberg Wittmer Ltd are serving as legal advisors.
Once the deal closes — targeted for before year-end 2026 — Samsung intends to acquire any remaining minority shares through a squeeze-out and delist PolyPeptide from the SIX Swiss Exchange, making it a wholly owned subsidiary.
Frequently Asked Questions
Why did Samsung Biologics need to buy PolyPeptide rather than build its own peptide facility?
Building a new GMP-certified peptide manufacturing site from scratch typically requires three to five or more years — encompassing construction, equipment installation, process validation, and regulatory inspection across multiple jurisdictions. PolyPeptide's six GMP-certified facilities have already completed that process and carry 70-plus years of accumulated regulatory track record with major pharmaceutical clients. Acquiring those facilities compresses Samsung's entry into peptide manufacturing from a decade-long buildout to the months it will take to close the deal.
What does this acquisition mean for the supply of GLP-1 drugs like Ozempic and Wegovy?
In the short term, not much changes: PolyPeptide will continue operating its existing contracts with current pharmaceutical clients, and the deal's integration will take time. Over the medium term, Samsung's financial resources could accelerate the SPPS capacity expansion projects already underway in Belgium, France, and Sweden. The GLP-1 shortage that ran from 2022 through early 2025 was formally resolved in February 2025, but supply remains structurally tight and demand continues to grow as more patients start treatment. Additional validated peptide API capacity anywhere in the chain ultimately reduces the risk of future shortages.
Does CDMO consolidation create new supply chain risks even as it adds capacity?
It can. When a small number of large CDMO operators control the majority of validated GMP-SPPS capacity for drugs millions of patients depend on, a quality failure, a regulatory enforcement action, or operational disruption at any one of them has fewer independent backups to absorb the impact. The current consolidation wave — Samsung, Bachem, CordenPharma, Lonza, Thermo Fisher all expanding — increases total capacity but reduces the number of independent decision-makers managing that capacity. The net effect on supply-chain resilience depends on whether expansion outpaces concentration, which will take years to assess.
Is the peptide manufacturing market a good long-term bet at the price Samsung paid?
Samsung paid a 40% premium above PolyPeptide's pre-rumor share price, supported by strong H1 2026 results showing 41.6% revenue growth and a 20.7% EBITDA margin — with 68% of that revenue now coming from the metabolic therapeutics segment that includes GLP-1 drugs. The global peptide CDMO market is projected to expand significantly through 2034 at roughly 10% annual growth. The question for investors is whether the GLP-1 injectable wave sustains as oral formulations enter the market, whether new drug entrants diversify away from pure peptide synthesis, and whether Samsung can integrate a specialized European peptide culture into its highly standardized Korean manufacturing framework quickly enough to justify the acquisition cost. Those are questions that will take several years to answer.
Related Articles
